BHCM
ELEV

Brevan Howard Capital Management’s Elevation Oncology ELEV Stock Holding History

Brevan Howard Capital Management’s Portfolio ELEV Stock Details ELEV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-28,358
Closed -$145K – 1140
2024
Q1 		$145K Buy
+28,358
New +$91.9K ﹤0.01% 852

Other funds holding ELEV

LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return

Brevan Howard Capital Management's ELEV Position: Q2 2024 in Review

Brevan Howard Capital Management sold out of Elevation Oncology (ELEV) in Q2 2024, closing a stake of 28,358 shares — an estimated $145K sold.

Brevan Howard Capital Management first reported a position in ELEV in Q1 2024 and held it in 1 quarter. The position peaked at $145K in Q1 2024. 81 funds tracked by Wall St. Rank hold ELEV as of Q2 2024.

  • Brevan Howard Capital Management reported no remaining Elevation Oncology position as of Q2 2024 after selling out during the quarter.
  • Brevan Howard Capital Management sold 28,358 Elevation Oncology shares in Q2 2024, an estimated $145K.
  • Brevan Howard Capital Management first reported a position in Elevation Oncology in Q1 2024 and held it in 1 quarter.
  • Brevan Howard Capital Management's Elevation Oncology position peaked at $145K in Q1 2024.
  • 81 funds tracked by Wall St. Rank held Elevation Oncology as of Q2 2024.

Based on Brevan Howard Capital Management's 13F filing for Q2 2024, filed 14 Aug 2024.